SLC5A2 and kidney disorder: (c) Diabetes is common at an early stage in patients with SMI, often exacerbated by antipsychotic treatment by altering glucose metabolism and promoting weight gain. Regular monitoring of HbA1c levels to assess long-term glucose control is important. Treatment plans should be tailored to both individual needs and comorbidities including ischaemic heart disease, heart failure, or nephropathy, where SGLT2 inhibitors or GLP-1 RAs are indicated. Management should extend beyond medications to include lifestyle modifications and collaborative care.